A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Recruiting now · Phase 3

Conditions studied: Diffuse Large B-cell Lymphoma

In brief

This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.

Key facts

Study ID

NCT06929624

Run by

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

People needed

280

Starts

2025-04-24

Expected to finish

2028-01-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
• Have received ≥1 line of systemic antitumor therapy.
• At least one bi-dimensionally measurable lesion.
• Expected survival of at least 3 months.
• Age ≥18 years old and under 80 years old.
• The patients voluntarily participated in the study, signed informed consent, had good compliance and were willing to cooperate with follow-up.

You may not qualify if…

• Central nervous system lymphoma involvement.
• Primary mediastinal (thymus) large B-cell lymphoma.
• Patients who have only one prior line therapy and are candidates for stem cell transplantation.
• A history of immunodeficiency.
• A history of severe cardiovascular disease.
• A history of other malignancies within 5 years prior to administration of the first dose.

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.